Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUOCOL-1: IOFA with ICG in Colorectal Surgery
NCT05168839Phase 3Recruiting
- Sponsor
- CHU de Besançon
- Start
- Sep 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of indocyanine green in colorectal cancer (CRC) (2 arms), sponsored by CHU de Besançon. Primary endpoint: Anastomotic leakage 90 days after surgery. Started Sep 2022; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05168839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168839.